Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

NCT05113537 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Castration-Resistant Prostate Carcinoma
Metastatic Prostate Adenocarcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Metastatic Castration-resistant Prostate Carcinoma
Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Abemaciclib
DRUG: Lutetium Lu 177-PSMA-617

Sponsor

Vadim S Koshkin

Collaborators

[object Object]
[object Object]